- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00984620
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
7. august 2015 oppdatert av: Boehringer Ingelheim
Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)
To compare the antiviral efficacy and safety of a 12-week with a 24-week treatment of BI 201335 at a dose of 120 mg once daily, with a 24-week background of pegylated interferon-alpha 2a (PegIFN) plus ribavirin (RBV), in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
160
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada
- 1220.40.1004 Boehringer Ingelheim Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- 1220.40.1001 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Ottawa, Ontario, Canada
- 1220.40.1002 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada
- 1220.40.1003 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canada
- 1220.40.1005 Boehringer Ingelheim Investigational Site
-
-
-
-
Mississippi
-
Tulepo, Mississippi, Forente stater
- 1220.40.002 Boehringer Ingelheim Investigational Site
-
-
New York
-
New York, New York, Forente stater
- 1220.40.007 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Germantown, Tennessee, Forente stater
- 1220.40.006 Boehringer Ingelheim Investigational Site
-
Jackson, Tennessee, Forente stater
- 1220.40.004 Boehringer Ingelheim Investigational Site
-
Nashville, Tennessee, Forente stater
- 1220.40.003 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Austin, Texas, Forente stater
- 1220.40.005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Clichy, Frankrike
- 1220.40.3303A Boehringer Ingelheim Investigational Site
-
Lille, Frankrike
- 1220.40.3305A Boehringer Ingelheim Investigational Site
-
Marseille, Frankrike
- 1220.40.3301A Boehringer Ingelheim Investigational Site
-
Montpellier, Frankrike
- 1220.40.3306A Boehringer Ingelheim Investigational Site
-
Paris, Frankrike
- 1220.40.3302A Boehringer Ingelheim Investigational Site
-
Rennes Cedex 09, Frankrike
- 1220.40.3304A Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bucharest, Romania
- 1220.40.4001 Boehringer Ingelheim Investigational Site
-
Bucharest, Romania
- 1220.40.4002 Boehringer Ingelheim Investigational Site
-
Bucharest, Romania
- 1220.40.4003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Berlin, Tyskland
- 1220.40.4902 Boehringer Ingelheim Investigational Site
-
Berlin, Tyskland
- 1220.40.4909 Boehringer Ingelheim Investigational Site
-
Düsseldorf, Tyskland
- 1220.40.4906 Boehringer Ingelheim Investigational Site
-
Düsseldorf, Tyskland
- 1220.40.4908 Boehringer Ingelheim Investigational Site
-
Hamburg, Tyskland
- 1220.40.4904 Boehringer Ingelheim Investigational Site
-
Mainz, Tyskland
- 1220.40.4905 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Linz, Østerrike
- 1220.40.4303 Boehringer Ingelheim Investigational Site
-
Wien, Østerrike
- 1220.40.4301 Boehringer Ingelheim Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 70 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion criteria:
- Chronic hepatitis C infection of genotype 1
- Therapy-naïve to interferon, pegylated interferon, and ribavirin
- HCV viral load > 100.000 IU/ml at screening
- Liver biopsy or fibroscan within two years prior to screening that provides evidence of any degree of fibrosis or cirrhosis
- Normal retinal finding on fundoscopy within 6 months prior to Day 1
- Age 18 to 70 years
Exclusion criteria:
- HCV of mixed genotype (1/2, 1/3, and 1/4) .
- Patients who have been previously treated with at least one dose of any protease inhibitor
- Evidence of liver disease due to causes other than chronic HCV infection
- Positive for HIV-1 or HIV-2 antibodies
- Hepatitis B virus (HBV) infection
- Decompensated liver disease, or history of decompensated liver disease
- Active malignancy or history of malignancy within the last 5 years
- History of alcohol or drug abuse (except cannabis) within the past 12 months.
- Body Mass Index < 18 or > 35 kg/m2.
- Usage of any investigational drugs within 30 days prior to enrolment
- Alpha fetoprotein value >100ng/mL at screening;
- Total bilirubin > 1.5 x ULN with ratio of direct/indirect > 1.
- ALT or AST level > 10 x ULN
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: short arm
patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e.
initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
|
BI 201335
Pegylated Interferon-alpha
Ribavirin (RBV)
|
|
Eksperimentell: long arm
patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e.
initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
|
BI 201335
Pegylated Interferon-alpha
Ribavirin (RBV)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Virological Response at Week 28 (W28VR)
Tidsramme: 28 weeks
|
Virological response at Week 28: The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at Week 28.
|
28 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rapid Virological Response at Week 4 (RVR)
Tidsramme: 4 weeks
|
Rapid virological response at week 4 (RVR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 4.
|
4 weeks
|
|
Virological Response at Week 24 (W24VR)
Tidsramme: 24 weeks
|
virological response at week 24 (W24VR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 24.
|
24 weeks
|
|
Virological Response at Week 36 (W36VR)
Tidsramme: 36 weeks
|
Virological response at week 36 (W36VR): the patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 36.
|
36 weeks
|
|
End of Treatment Response (ETR)
Tidsramme: up to 48 weeks
|
End of Treatment Response (ETR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at end of all therapy.
|
up to 48 weeks
|
|
Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy
Tidsramme: 72 weeks
|
Sustained Virological Response (SVR24) at 24 weeks: The patients who reached plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at 24 weeks after completion of all Hepatitis C virus (HCV) therapy.
|
72 weeks
|
|
Viral Load (HCV RNA) at All Visits During Treatment and Follow-up
Tidsramme: From baseline to 72 weeks
|
Viral load of Hepatitis C virus Ribonucleic acid (HCV RNA) at all visits during treatment (TRT) and follow-up, ie.
change from baseline viral load at all visits.
|
From baseline to 72 weeks
|
|
Time to Reach a Plasma HCV RNA Level BLD While on Treatment
Tidsramme: 48 weeks
|
Time to reach a plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) level below the lower limit of detection (BLD) while on treatment
|
48 weeks
|
|
Laboratory Test Abnormalities and Study Medication Tolerabilities
Tidsramme: 48 weeks
|
Participants with possible clinically significant laboratory test abnormalities observed in functional groups: Haematology, Coagulation, Electrolytes, Enzymes, Substrates and Differentials, automatic.
|
48 weeks
|
|
Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination
Tidsramme: 48 weeks
|
No number of participants with clinically relevant abnormalities in vital signs and physical examination.
|
48 weeks
|
|
Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)
Tidsramme: baseline and 48 weeks
|
Change from baseline (CFB) in Red blood cells.
|
baseline and 48 weeks
|
|
Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)
Tidsramme: baseline and 48 weeks
|
Change from baseline (CFB) in haematocrit and Eosinophils.
|
baseline and 48 weeks
|
|
Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)
Tidsramme: baseline and 48 weeks
|
Change from baseline (CFB) in Platelets and white blood cells.
|
baseline and 48 weeks
|
|
Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)
Tidsramme: baseline and 48 weeks
|
Change from baseline (CFB) in Sodium, Bicarbonate, Cholesterol total, Triglyceride, and Glucose.
|
baseline and 48 weeks
|
|
Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)
Tidsramme: baseline and 48 weeks
|
Change from baseline (CFB) in AST/GOT, ALT/GPT, Alka.
phosphatase, GGT, Creatine kinase, Lipase, and Amylase.
|
baseline and 48 weeks
|
|
Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)
Tidsramme: baseline and 48 weeks
|
Change from baseline (CFB) in PT-INR (ratio).
|
baseline and 48 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2009
Primær fullføring (Faktiske)
1. april 2011
Datoer for studieregistrering
Først innsendt
24. september 2009
Først innsendt som oppfylte QC-kriteriene
24. september 2009
Først lagt ut (Anslag)
25. september 2009
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
7. september 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. august 2015
Sist bekreftet
1. august 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Leversykdommer
- Flaviviridae-infeksjoner
- Hepatitt, viral, menneskelig
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Hepatitt
- Hepatitt A-virus
- Hepatitt C
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Antimetabolitter
- Antineoplastiske midler
- Immunologiske faktorer
- Interferoner
- Interferon-alfa
- Ribavirin
Andre studie-ID-numre
- 1220.40
- 2009-012579-90 (EudraCT-nummer: EudraCT)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .